M D Hornstein

No ORCID on file · 21 papers in corpus
other 1999
Fertility and sterility ·doi:10.1016/s0015-0282(99)00300-3

OBJECTIVE: To determine whether age, diagnosis, and cycle number influence cycle fecundity associated with gonadotropin-induced controlled ovarian hyperstimulation/IUI. DESIGN: Retrospective analysis. SETTING: The Center for Reproductive …

article 1998
Journal of assisted reproduction and genetics ·doi:10.1023/a:1023048318719

PurposeThe effect of endometriomas on oocyte quality, embryo quality, and pregnancy rates in in vitro fertilization (IVF) cycles was evaluated.MethodsForty-five women had "chocolate" cysts aspirated at the time of oocyte retrieval, and cyst…

article 1998
Obstetrics and gynecology ·doi:10.1016/s0029-7844(97)00620-0

OBJECTIVE: To evaluate the efficacy and safety of a GnRH agonist, leuprolide acetate depot, alone and in combination with three hormonal add-back regimens in the management of endometriosis-associated pelvic pain. METHODS: Two hundred and o…

rct 1998
JAMA ·doi:10.1001/jama.280.12.1067

CONTEXT: Short-term intermittent administration of parathyroid hormone (PTH) prevents bone loss from the spine in women treated with a gonadotropin-releasing hormone (GnRH) analog. However, the effects of a longer period of PTH administrati…

other 1998
The Journal of reproductive medicine
other 1997
Human Reproduction ·doi:10.1093/humrep/12.1.143

Women with melanoma and its precursor lesions, dysplastic naevi, have a higher prevalence of reproductive disorders than women without melanotic lesions. This association appears strongest among young women with dysplastic naevi and endomet…

other 1997
Fertility and sterility ·doi:10.1016/s0015-0282(97)00373-7

OBJECTIVE: To examine serum androgen profiles in women undergoing ovarian stimulation with exogenous gonadotropins in the setting of IVF-ET. DESIGN: Prospective study. SETTING: University hospital IVF-ET program. PATIENT(S): Seventeen ov…

article 1997
Fertility and sterility ·doi:10.1016/s0015-0282(97)81432-x

ObjectiveTo assess the efficacy, safety, and effect on bone mineral density of a 3-month course of retreatment with intranasal nafarelin acetate for recurrent symptoms of endometriosis.DesignMulticenter, open-label, nonrandomized clinical t…

review 1997
Seminars in reproductive endocrinology ·doi:10.1055/s-2008-1068757

Agonistic analogs of GnRH have emerged as effective drugs in the treatment of pelvic pain associated with endometriosis. Iatrogenic hypoestrogenism is the fundamental mechanism through which GnRH agonists induce regression of the exquisitel…

article 1997
Fertility and sterility ·doi:10.1016/s0015-0282(97)00360-9

ObjectiveTo evaluate the efficacy of the GnRH agonist (GnRH-a) nafarelin compared with placebo administered for 6 months after reductive laparoscopic surgery for symptomatic endometriosis.DesignRandomized, prospective, placebo-controlled, m…

article 1996
Molecular human reproduction ·doi:10.1093/molehr/2.3.149

To explore a possible connection between endometriosis, Müllerian anomalies, and possession of the N314D allele of the gene for galactose-1-phosphate uridyl transferase (GALT), we studied 33 women with endometriosis attending a fertility cl…

letter 1995
International Journal of Gynecology & Obstetrics ·doi:10.1016/0020-7292(94)02253-u
article 1995
Human Reproduction ·doi:10.1093/oxfordjournals.humrep.a136064

Serum CA 125 concentrations are elevated in some women with endometriosis; however, the low sensitivity and specificity of the assay have made it impractical to use it as a diagnostic test for endometriosis. Recently a second-generation CA …

article 1995
Fertility and sterility ·doi:10.1016/s0015-0282(16)57530-x

ObjectivesTo determine the effectiveness of a 3-month course of nafarelin and, furthermore, to determine the long-term efficacy in patients treated for 3 and 6 months with nafarelin for symptoms associated with endometriosis.DesignDouble-bl…

article 1994
American journal of obstetrics and gynecology ·doi:10.1016/0002-9378(94)90136-8

ObjectiveThe study intent was to examine long-term effects on bone mass of 3 or 6 months of nafarelin therapy for endometriosis.Study designWomen with established endometriosis (N = 173) were randomized to receive nafarelin (200 micrograms …

rct 1994
New England Journal of Medicine ·doi:10.1056/NEJM199412153312404

BACKGROUND: Analogues of gonadotropin-releasing hormone (GnRH) are often given to induce hypogonadism in women who have estrogen-dependent disorders such as endometriosis and uterine leiomyomas. Because estrogen deficiency causes bone loss,…

retraction 1993
Fertility and sterility ·doi:10.1016/s0015-0282(16)56090-7

ObjectiveTo evaluate the safety and efficacy of leuprolide acetate depot (LA, Lupron; TAP Pharmaceuticals, Deerfield, IL) plus daily conjugated equine estrogens (Es, Premarin; Wyeth-Ayerst Laboratories, Philadelphia, PA), and medroxyprogest…

article 1993
Fertility and sterility ·doi:10.1016/s0015-0282(16)55921-4

ObjectiveTo assess the degree of intraobserver and interobserver variability in endometriosis staging using the revised American Fertility Society (AFS) classification of endometriosis.DesignVideotapes of laparoscopies of 20 patients with e…

other 1992
Fertility and sterility ·doi:10.1016/s0015-0282(16)55204-2

OBJECTIVE: To examine the serum levels of CA-125 in the menstrual, follicular, and luteal phases of the menstrual cycle in women with endometriosis and to determine if serum CA-125 levels drawn during menses improve the clinical utility of …

other 1992
Fertility and sterility ·doi:10.1016/s0015-0282(16)55087-0

STUDY OBJECTIVE: To determine the effect of baseline complex ovarian cysts on controlled ovarian hyperstimulation and in vitro fertilization (IVF) outcome. DESIGN: Retrospective analysis with stratification by stimulation regimen and the p…

article 1990
Fertility and sterility ·doi:10.1016/s0015-0282(16)53273-7

The purpose of this randomized double blind prospective trial was to study the efficacy and safety of two doses of oral gestrinone in the treatment of endometriosis. Six patients received gestrinone 1.25 mg twice weekly (group I) and six pa…